Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupThoracic TumorsDiseaseLung Carcinoma, Non-Small CellSubgroupICD10C34.-MeSHSequenceNIVO360/PACL200/CRBP6/BEVA15, NSCLC (PID1929) -|- NIVO360/BEVA15, maint. (PID2126)ChemotherapyChemo-substanceBevacizumabCarboplatinNivolumabPaclitaxelChemo-substanceBevacizumabCarboplatinNivolumabPaclitaxelChemo-substanceBevacizumabCarboplatinNivolumabPaclitaxelChemo-substanceBevacizumabCarboplatinNivolumabPaclitaxelNo. Substances24 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronPegfilgrastimSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronPegfilgrastimSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronPegfilgrastimSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronPegfilgrastimNo. Substances17Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaHypertensionNeuropathyNeutropeniaProteinuriaRashThrombocytopenia below 50 000/µl only studiesPublicationAuthorSugawara SDiseaseAdenokarzinom nichtkleinzelliges Lungenkarzinom, Stadium IIIb/IV oder rezidiviert, ECOG 0-1OriginDepartment of Pulmonary Medicine, Sendai Kousei Hospital, Miyagi, JapanProtocols in Revision 2 protocols foundProtocols under revision.Nivolumab 360 / paclitaxel 200 / carboplatin 6 / bevacizumab 15 - Nivolumab 360 / bevacizumab 15, non-small cell lung cancer, maintenance (PID2126)Nivolumab 360 / Paclitaxel 200 / Carboplatin 6 / Bevacizumab 15, Non-Small Cell Lung Cancer (PID1929)